MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Overview
TSX:MDP - CA58410Q2036 - Common Stock
MDP.CA Key Statistics, Chart & Performance
The current stock price of MDP.CA is 3.11 CAD. In the past month the price increased by 11.07%. In the past year, price increased by 26.94%.
MDP.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.91 | 3.71B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 2.09B | ||
| CRON.CA | CRONOS GROUP INC | 50.57 | 1.36B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 6.62 | 788.04M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 646.73M | ||
| TSND.CA | TERRASCEND CORP | N/A | 565.50M | ||
| DHT-U.CA | DRI HEALTHCARE TRUST | 4.7 | 559.49M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 553.51M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 415.13M | ||
| HITI.CA | HIGH TIDE INC | N/A | 402.75M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 23.91 | 388.47M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 310.30M |
Related stock screener links
About MDP.CA
Company Profile
Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and treatment solutions focusing on therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. The company is headquartered in Toronto, Ontario. The company went IPO on 2012-03-03. The firm has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. The company operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Company Info
MEDEXUS PHARMACEUTICALS INC
10 King Street East, Suite 600
TORONTO ONTARIO H3E 1A2 CA
CEO: Kenneth d’Entremont
Employees: 98
Phone: 18774225242
MEDEXUS PHARMACEUTICALS INC / MDP.CA FAQ
What is the stock price of MEDEXUS PHARMACEUTICALS INC today?
The current stock price of MDP.CA is 3.11 CAD. The price increased by 9.12% in the last trading session.
What is the ticker symbol for MEDEXUS PHARMACEUTICALS INC stock?
The exchange symbol of MEDEXUS PHARMACEUTICALS INC is MDP and it is listed on the Toronto Stock Exchange exchange.
On which exchange is MDP.CA stock listed?
MDP.CA stock is listed on the Toronto Stock Exchange exchange.
What is the price forecast or stock price prediction for MEDEXUS PHARMACEUTICALS INC stock?
11 analysts have analysed MDP.CA and the average price target is 6.3 CAD. This implies a price increase of 102.64% is expected in the next year compared to the current price of 3.11. Check the MEDEXUS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MEDEXUS PHARMACEUTICALS INC worth?
MEDEXUS PHARMACEUTICALS INC (MDP.CA) has a market capitalization of 100.33M CAD. This makes MDP.CA a Micro Cap stock.
How many employees does MEDEXUS PHARMACEUTICALS INC have?
MEDEXUS PHARMACEUTICALS INC (MDP.CA) currently has 98 employees.
What are the support and resistance levels for MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
MEDEXUS PHARMACEUTICALS INC (MDP.CA) has a support level at 2.92 and a resistance level at 3.23. Check the full technical report for a detailed analysis of MDP.CA support and resistance levels.
Is MEDEXUS PHARMACEUTICALS INC (MDP.CA) expected to grow?
The Revenue of MEDEXUS PHARMACEUTICALS INC (MDP.CA) is expected to decline by -5.4% in the next year. Check the estimates tab for more information on the MDP.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MDP.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MDP.CA, evaluating the profitability, health, valuation and growth aspects
- MEDEXUS PHARMACEUTICALS INC (MDP.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MEDEXUS PHARMACEUTICALS INC (MDP.CA) Sales and EPS estimates to see what analysts future expectations are.
- MEDEXUS PHARMACEUTICALS INC (MDP.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MEDEXUS PHARMACEUTICALS INC (MDP.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Chart to make your own analysis
- MEDEXUS PHARMACEUTICALS INC (MDP.CA) Latest news and press-releases to stay up to date.
Does MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock pay dividends?
MDP.CA does not pay a dividend.
When does MEDEXUS PHARMACEUTICALS INC (MDP.CA) report earnings?
MEDEXUS PHARMACEUTICALS INC (MDP.CA) will report earnings on 2025-11-07.
What is the Price/Earnings (PE) ratio of MEDEXUS PHARMACEUTICALS INC (MDP.CA)?
The PE ratio for MEDEXUS PHARMACEUTICALS INC (MDP.CA) is 103.67. This is based on the reported non-GAAP earnings per share of 0.03 and the current share price of 3.11 CAD. Check the full fundamental report for a full analysis of the valuation metrics for MDP.CA.
MDP.CA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to MDP.CA. When comparing the yearly performance of all stocks, MDP.CA turns out to be only a medium performer in the overall market: it outperformed 62.49% of all stocks.
MDP.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to MDP.CA. MDP.CA has only an average score on both its financial health and profitability.
MDP.CA Financial Highlights
Over the last trailing twelve months MDP.CA reported a non-GAAP Earnings per Share(EPS) of 0.03. The EPS decreased by -50% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.76% | ||
| ROA | 0.52% | ||
| ROE | 1.52% | ||
| Debt/Equity | 0 |
MDP.CA Forecast & Estimates
11 analysts have analysed MDP.CA and the average price target is 6.3 CAD. This implies a price increase of 102.64% is expected in the next year compared to the current price of 3.11.
For the next year, analysts expect an EPS growth of -175.75% and a revenue growth -5.4% for MDP.CA